CA
IMGN

Centerpoint Advisors’s Immunogen Inc IMGN Stock Holding History

Centerpoint Advisors’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-242
Closed -$1K – 676
2022
Q4 		$1K Hold
242
– – ﹤0.01% 476
2022
Q3 		$1K Hold
242
– – ﹤0.01% 379
2022
Q2 		$1K Hold
242
– – ﹤0.01% 385
2022
Q1 		$1K Hold
242
– – ﹤0.01% 398
2021
Q4 		$2K Buy
+242
New +$1.5K ﹤0.01% 357

Other funds holding IMGN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Centerpoint Advisors's IMGN Position: Q1 2023 in Review

Centerpoint Advisors sold out of Immunogen Inc (IMGN) in Q1 2023, closing a stake of 242 shares — an estimated $1K sold.

Centerpoint Advisors first reported a position in IMGN in Q4 2021 and held it in 5 quarters. The position peaked at $2K in Q4 2021. 190 funds tracked by Wall St. Rank hold IMGN as of Q1 2023.

  • Centerpoint Advisors reported no remaining Immunogen Inc position as of Q1 2023 after selling out during the quarter.
  • Centerpoint Advisors sold 242 Immunogen Inc shares in Q1 2023, an estimated $1K.
  • Centerpoint Advisors first reported a position in Immunogen Inc in Q4 2021 and held it in 5 quarters.
  • Centerpoint Advisors's Immunogen Inc position peaked at $2K in Q4 2021.
  • 190 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2023.

Based on Centerpoint Advisors's 13F filing for Q1 2023, filed 3 May 2023.